Kim Tae Hwan, Yoo Sun Dong, Lee Hye Suk, Lee Kyoung Mee, Seok Su Hyun, Kim Min Gi, Jung Byung Hwa, Kim Min Gyu, Shin Beom Soo
School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea.
College of Pharmacy, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea.
Drug Metab Pharmacokinet. 2015 Apr;30(2):168-73. doi: 10.1016/j.dmpk.2014.12.003. Epub 2014 Dec 9.
This study aimed to evaluate the potential of α-cedrene as a new anti-obesity drug by characterizing absorption, metabolism and pharmacokinetics in rats. α-Cedrene was administered intravenously (10 and 20 mg/kg) and orally (50 and 100 mg/kg) to female and male Sprague-Dawley rats. Blood, tissues, urine, and feces were collected at predetermined times. α-Cedrene concentrations were determined by a validated gas chromatography-tandem mass spectrometry (GC-MS/MS). A gas chromatography-mass selective detection (GC-MSD) method was used to identify the major metabolite. After i.v. injection, α-cedrene exhibited a rapid clearance (98.4-120.3 ml/min/kg), a large distribution volume (35.9-56.5 l/kg), and a relatively long half-life (4.0-6.4 h). Upon oral administration, it was slowly absorbed (Tmax = 4.4 h) with bioavailability of 48.7-84.8%. No gender differences were found in its pharmacokinetics. Upon oral administration, α-cedrene was highly distributed to tissues, with the tissue-to-plasma partition coefficients (Kp) far greater than unity for all tissues. In particular, its distribution to lipid was notably high (Kp = 132.0) compared to other tissues. A mono-hydroxylated metabolite was identified as a preliminary metabolite in rat plasma. These results suggest that α-cedrene has the favorable pharmacokinetic characteristics to be further tested as an anti-obesity drug in clinical studies.
本研究旨在通过表征α-雪松烯在大鼠体内的吸收、代谢和药代动力学,评估其作为新型抗肥胖药物的潜力。将α-雪松烯以静脉注射(10和20 mg/kg)和口服(50和100 mg/kg)的方式给予雌性和雄性Sprague-Dawley大鼠。在预定时间收集血液、组织、尿液和粪便。通过经过验证的气相色谱-串联质谱法(GC-MS/MS)测定α-雪松烯浓度。采用气相色谱-质量选择性检测(GC-MSD)方法鉴定主要代谢物。静脉注射后,α-雪松烯表现出快速清除率(98.4 - 120.3 ml/min/kg)、较大分布体积(35.9 - 56.5 l/kg)和相对较长的半衰期(4.0 - 6.4 h)。口服给药后,其吸收缓慢(Tmax = 4.4 h),生物利用度为48.7 - 84.8%。其药代动力学未发现性别差异。口服给药后,α-雪松烯在组织中高度分布,所有组织的组织-血浆分配系数(Kp)均远大于1。特别是,与其他组织相比,其在脂质中的分布显著较高(Kp = 132.0)。一种单羟基化代谢物被鉴定为大鼠血浆中的初步代谢物。这些结果表明,α-雪松烯具有良好的药代动力学特性,可在临床研究中作为抗肥胖药物进一步测试。